NCT05370521 - A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 15, 2022

Primary Completion Date

August 3, 2023

Study Completion Date

August 31, 2023

Conditions

Polycystic Ovary Syndrome

Interventions

DRUG

Tildacerfont

Oral tablet formulation taken once daily.

DRUG

Placebo

Non-active dosage form taken once daily.

Trial Locations (21)

14221

Spruce Study Site, Williamsville

19104

Spruce Study Site, Philadelphia

26506

Spruce Study Site, Morgantown

27612

Spruce Study Site, Raleigh

32792

Spruce Study Site, Winter Park

33173

Spruce Study Site, Miami

33461

Spruce Study Site, Lake Worth

33759

Spruce Study Site, Clearwater

44106

Spruce Study Site, Cleveland

45219

Spruce Study Site, Cincinnati

48034

Spruce Study Site, Southfield

67226

Spruce Study Site, Wichita

76022

Spruce Study Site, Bedford

77024

Spruce Study Site, Houston

77030

Spruce Study Site, Houston

83404

Spruce Study Site, Idaho Falls

94158

Spruce Study Site, San Francisco

95817

Spruce Study Site, Sacramento

06519

Spruce Study Site, New Haven

02115

Spruce Study Site, Boston

02720

Spruce Study Site, Fall River